Phase 3Initiation

KPL-387

Recurrent pericarditis

KNSAKiniksa Pharmaceuticals

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: KPL-387
Development stage: Phase 3
Event type: Initiation
Indication: Recurrent pericarditis

Research summary

What is being tracked?

This catalyst tracks a Phase 3 initiation for KPL-387 in Recurrent pericarditis. The expected timing is based on the latest available company guidance and may change.

Development notes

07/28/26:- Phase 2 data supported 300 mg monthly; PASTORALE Phase 3 dosing and transition study ongoing.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source